NICE hits Keytruda with ‘no’ for urothelial cancer
The rejection comes after a review of new evidence collected while the blockbuster was available via the Cancer Drugs Fund.
Read More
Tag: Cancer Drugs Fund
Lynparza now available on Cancer Drugs Fund
The treatment reduces the risk of disease progression or death in such patients by 70% vs placebo.
Read More
NICE appraisal for BMS kidney cancer immunotherapy combination
The Institute gave a positive FAD to the Opdivo and Yervoy combination in renal cell carcinoma, approving funding via the Cancer Drugs Fund.
Read More
NICE nod for breast cancer delay drug
Eli Lilly’s Verzenio has been recommended for use within the Cancer Drugs Fund by NICE.
Read More
AZ’ Imfinzi to be funded for NHS use via CDF
AstraZeneca’s PD-L1 inhibitor Imfinzi will be made available on the NHS in England immediately for patients with locally advanced unresectable non-small-cell lung cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
